HUE049152T2 - Hosszantartó hatású GLP-1 peptidek alkalmazása - Google Patents

Hosszantartó hatású GLP-1 peptidek alkalmazása

Info

Publication number
HUE049152T2
HUE049152T2 HUE13737808A HUE13737808A HUE049152T2 HU E049152 T2 HUE049152 T2 HU E049152T2 HU E13737808 A HUE13737808 A HU E13737808A HU E13737808 A HUE13737808 A HU E13737808A HU E049152 T2 HUE049152 T2 HU E049152T2
Authority
HU
Hungary
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
HUE13737808A
Other languages
English (en)
Hungarian (hu)
Inventor
Christine Bjorn Jensen
Mads Frederik Rasmussen
Milan Zdravkovic
Peter Kristensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of HUE049152T2 publication Critical patent/HUE049152T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE13737808A 2012-07-01 2013-06-21 Hosszantartó hatású GLP-1 peptidek alkalmazása HUE049152T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01

Publications (1)

Publication Number Publication Date
HUE049152T2 true HUE049152T2 (hu) 2020-09-28

Family

ID=65858459

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13737808A HUE049152T2 (hu) 2012-07-01 2013-06-21 Hosszantartó hatású GLP-1 peptidek alkalmazása

Country Status (17)

Country Link
US (2) US9764003B2 (enExample)
EP (3) EP4406593A3 (enExample)
JP (1) JP6059802B2 (enExample)
AU (3) AU2013286177B2 (enExample)
BR (1) BR112014032938A2 (enExample)
CA (1) CA2877056A1 (enExample)
DK (1) DK2866825T3 (enExample)
ES (2) ES2796839T3 (enExample)
HR (2) HRP20251088T1 (enExample)
HU (1) HUE049152T2 (enExample)
MX (3) MX376058B (enExample)
PL (2) PL3689365T3 (enExample)
PT (1) PT2866825T (enExample)
RS (2) RS60432B1 (enExample)
RU (2) RU2018117557A (enExample)
SI (1) SI2866825T1 (enExample)
WO (1) WO2014005858A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180425T1 (hr) 2010-12-16 2018-04-20 Novo Nordisk A/S Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
JP6059802B2 (ja) 2012-07-01 2017-01-11 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
CN107074109B (zh) * 2014-10-16 2019-10-25 洋马株式会社 拖拉机
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
IL322968A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical treatment
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
JP2022521551A (ja) * 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
EP4414031A3 (en) * 2019-11-06 2025-02-05 Novo Nordisk A/S Glp-1 receptor agonists in dementia
WO2021136303A1 (zh) * 2019-12-30 2021-07-08 甘李药业股份有限公司 长效glp-1化合物
MX2022009844A (es) * 2020-02-18 2022-09-05 Novo Nordisk As Composiciones y usos del peptido similar al glucagon-1 (glp-1).
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
WO2023049518A1 (en) 2021-09-27 2023-03-30 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JP2024544920A (ja) 2021-11-10 2024-12-05 アイ２オー セラピューティクス，インク． イオン液体組成物
CN115850438B (zh) * 2021-12-28 2023-05-12 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
PE20250741A1 (es) 2022-02-23 2025-03-13 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
EP4568664A1 (en) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
WO2025024455A1 (en) 2023-07-24 2025-01-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
PL3300721T5 (pl) 2003-11-20 2025-11-17 Novo Nordisk A/S Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
ES2735533T3 (es) 2004-11-12 2019-12-19 Novo Nordisk As Formulaciones estables de GLP-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0709964A2 (pt) 2006-04-14 2011-08-02 Mannkind Corp formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
WO2008116088A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
SI2373681T1 (sl) 2008-12-10 2017-05-31 Glaxosmithkline Llc Corporation Service Company Farmacevtski sestavki albiglutida
EA029759B1 (ru) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
HUE027229T2 (en) * 2009-12-16 2016-08-29 Novo Nordisk As Double acylated glp-1 derivatives
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
HRP20180425T1 (hr) 2010-12-16 2018-04-20 Novo Nordisk A/S Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
JP6059802B2 (ja) 2012-07-01 2017-01-11 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用

Also Published As

Publication number Publication date
AU2020202573A1 (en) 2020-05-07
EP2866825A1 (en) 2015-05-06
MX2020010693A (es) 2020-11-06
RS60432B1 (sr) 2020-07-31
US9764003B2 (en) 2017-09-19
EP3689365B1 (en) 2025-08-06
RS67258B1 (sr) 2025-10-31
AU2020202573B2 (en) 2023-04-20
PT2866825T (pt) 2020-07-15
EP2866825B1 (en) 2020-04-08
EP4406593A3 (en) 2024-10-23
US20180085435A1 (en) 2018-03-29
ES3041720T3 (en) 2025-11-14
US20150190474A1 (en) 2015-07-09
JP2015522573A (ja) 2015-08-06
RU2015101826A (ru) 2016-08-20
RU2018117557A (ru) 2019-03-22
PL2866825T3 (pl) 2021-02-22
EP3689365A1 (en) 2020-08-05
HRP20251088T1 (hr) 2025-11-07
PL3689365T3 (pl) 2025-11-12
HRP20200889T1 (hr) 2020-09-04
AU2013286177A1 (en) 2015-01-15
EP4406593A2 (en) 2024-07-31
RU2657573C2 (ru) 2018-06-14
ES2796839T3 (es) 2020-11-30
WO2014005858A1 (en) 2014-01-09
AU2018202504B2 (en) 2020-05-07
MX2019008148A (es) 2019-09-05
BR112014032938A2 (pt) 2017-08-01
MX366405B (es) 2019-07-08
EP3689365C0 (en) 2025-08-06
AU2018202504A1 (en) 2018-05-10
MX376058B (es) 2025-03-07
RU2018117557A3 (enExample) 2021-08-20
US10335462B2 (en) 2019-07-02
SI2866825T1 (sl) 2020-07-31
JP6059802B2 (ja) 2017-01-11
DK2866825T3 (da) 2020-06-08
AU2013286177B2 (en) 2018-04-26
MX2014014946A (es) 2015-04-08
CA2877056A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
HUE049152T2 (hu) Hosszantartó hatású GLP-1 peptidek alkalmazása
IL236554B (en) Glucagon analogues
DK3085777T3 (da) Polypeptid
CO7020866A2 (es) Péptidos terapéuticos
DK3536310T3 (da) Sprøjte
DK3685826T3 (da) Sprøjte
EP2692380A4 (en) SYRINGE
EP2832391A4 (en) SYRINGE
BR112014004902A2 (pt) peptídeos
HRP20181569T1 (hr) Peptidi kao agonisti oksitocina
PL2928905T3 (pl) Sposób oczyszczania białek terapeutycznych
IL237914A0 (en) Benzamides
EP2812347A4 (en) PEPTIDE INDUCING AUTOPHAGIA
FI20116212L (fi) Polypeptidi
EP2913076A4 (en) SYRINGE
HUE053273T2 (hu) Opioid készítmények
CL2014002180A1 (es) Peptidos antomicrobianos
FR2993464B1 (fr) Pansement interface autoporte
EP2714717A4 (en) PHOENIXINPEPTIDE
TH1401007523A (th) การเพาะเลี้ยงสัตว์น้ำแบบมิกโซโทรฟิค (mixotrophic)
DK2895505T3 (da) Glucagonanaloger
ITRM20120442A1 (it) Interfaccia paziente-struttura sanitaria
EE01070U1 (et) Stesegu
EP2885023A4 (en) SYRINGE
UA24071S (uk) Набір столових приборів